Swabs typically don’t attract much attention. Small, simple, inexpensive, used quickly and discarded, they hardly seem to merit the title of “medical device.” But amid the COVID-19 pandemic, the lowly swab has gained enormous importance. Without it, testing grinds to a halt and detecting the virus becomes extremely difficult.
So when demand for swabs exploded last spring and supplies became scarce, Paul Jannetto, Ph.D., a laboratory director in Mayo Clinic’s Department of Laboratory Medicine and Pathology who serves as vice chair of the department’s Supply Chain Management Committee, faced a serious problem.
There are two main manufacturers of flocked nasopharyngeal swabs — the standard swab for molecular SARS-CoV-2 testing. While the manufacturers worked to ramp up production to meet demand, Dr. Jannetto and his colleagues in Supply Chain Management were tasked with the job of looking for alternative vendors and swab types.
What sounded like a straightforward assignment — find more swabs — became a massive effort that involved numerous departments and experts, and culminated in Mayo Clinic for the first time designing, testing and mass-manufacturing a new medical device listed with the Food and Drug Administration: the 3D-printed mid-turbinate swab.
That achievement reinforced a critical link in the supply chain, allowing Mayo Clinic to press forward with confidence as it develops an at-home COVID-19 test and easing the burden on health care teams that administer in-person tests.
Uncovering an appealing alternative
One of the first people to weigh in on the swab dilemma was Bobbi Pritt, M.D., chair of Mayo’s Division of Clinical Microbiology. She knew from previous research that nasal mid-turbinate swabs could be as effective as nasopharyngeal swabs in detecting viral infections of the upper respiratory tract.
Dr. Pritt saw benefits to pursuing the use of mid-turbinate swabs. First, they are more comfortable for patients because they don’t need to reach as far back into the nasal passage as nasopharyngeal swabs to obtain a sample.
Read the rest of the article on Mayo Clinic Laboratories Insights.
‘Courtesy: Mayo Clinic News Network.’[/vc_message]
Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components
